Controversial Stem-Cell Company Moves Treatment Out of the United States
By David Cyranoski,
Nature
| 01. 30. 2013
Celltex to send patients to Mexico.
US citizens who had pinned their hopes on a company being able to offer stem-cell treatments close to home will now need to travel a little farther. Celltex Therapeutics of Houston, Texas, stopped treating patients in the United States last year following a warning from regulators. A 25 January e-mail to Celltex customers indicates that the firm will now follow in the footsteps of many other companies offering unproven stem-cell therapies and send its patients abroad for treatment — but only to Mexico.
The stem-cell treatments offered by Celltex involved extracting adult stem cells from a patient, culturing them and then reinjecting them in a bid to replenish damaged tissue. It had been offering the treatment for more than a year — with one of its high-profile customers being Texas governor, Rick Perry — when the US Food and Drug Administration (FDA)
wrote to the company on 24 September 2012 advising it that the stem cells it harvested and grew were more than “minimally manipulated” during Celltex's procedures. As such, the FDA regarded the cells as drugs, which would require...
Related Articles
By [cites CGS' Katie Hasson], KCBS Radio | 11.19.2025
This is Ask An Expert, where every weekday at 9:20am, KCBS Radio is giving you direct access to top experts in various fields. Today: Gene-editing technology allows scientists to work with DNA in unprecedented ways, but there are larger scientific...
By Alice Miranda Ollstein and Megan Messerly, Politico | 10.25.2025
By Ben Foldy, The Wall Street Journal | 10.21.2025
AnnaMaria Gallozzi and her husband wanted to have a second child last year. Because Gallozzi has advanced breast cancer, the couple sought out a surrogate who could carry their baby.
They used crowdfunding and took out a second mortgage on...
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...